Fintel reports that on June 18, 2024, Stifel initiated coverage of Third Harmonic Bio (NasdaqGM:THRD) with a Buy recommendation.
Analyst Price Forecast Suggests 24.19% Upside
As of June 12, 2024, the average one-year price target for Third Harmonic Bio is 15.30. The forecasts range from a low of 12.12 to a high of $18.90. The average price target represents an increase of 24.19% from its latest reported closing price of 12.32.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Third Harmonic Bio is 0MM. The projected annual non-GAAP EPS is -2.38.
What is the Fund Sentiment?
There are 150 funds or institutions reporting positions in Third Harmonic Bio. This is an increase of 14 owner(s) or 10.29% in the last quarter. Average portfolio weight of all funds dedicated to THRD is 0.11%, an increase of 29.07%. Total shares owned by institutions decreased in the last three months by 0.05% to 38,129K shares. 
The put/call ratio of THRD is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
Atlas Venture Life Science Advisors holds 10,908K shares representing 26.64% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 5,779K shares representing 14.11% ownership of the company. No change in the last quarter.
Bvf holds 4,366K shares representing 10.66% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 3,182K shares representing 7.77% ownership of the company. No change in the last quarter.
General Atlantic holds 2,959K shares representing 7.23% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
